stock
APGE · Apogee Therapeutics, Inc.
What Apogee Therapeutics, Inc. reports to the SEC, read from its filings.
Open in the appPrice
The live APGE price and today's change.
Sign in to see thisChart
Thirty days of daily bars, with signal levels drawn on them.
Sign in to see thisSignals
The latest signal group Nakagai's scanner recorded on APGE.
Sign in to see thisOptions positioning
Gamma exposure levels from the options market.
Sign in to see thisTechnicals
Trend, momentum and volatility gauges per timeframe.
Sign in to see thisWhat it is
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Filer (SEC EDGAR)
- EDGAR filing index
- Shares outstanding
- Not reported.
Key stats
Valuation
- P/E
- Locked
- P/S
- Locked
- P/B
- Locked
- Enterprise value
- Locked
- EV/EBIT
- Locked
- FCF yield
- Locked
Margins
- Gross
- —
- Operating
- —
- Net
- —
Returns
- ROE
- —
- ROA
- -22.0%
Health
- Current ratio
- 26.4x
- Debt/equity
- —
Deep value
- NCAV
- $850.52M
- NCAV per share
- —
- Price/NCAV
- Locked
- NNWC
- -$35.64M
- NNWC per share
- —
- Price/NNWC
- Locked
Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.
Sign in to see thisDebt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
| Period end | Revenue (not reported by this company) | Gross profit (not reported by this company) | Operating income | Net income | Filing |
|---|---|---|---|---|---|
| 2026-06-30 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$96.00M | -$85.85M | 10-Q filed 2026-08-10 |
| 2026-03-31 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$82.77M | -$74.11M | 10-Q filed 2026-08-10 Assembled from more than one filing; the filing above is only the newest of them. |
| 2025-12-31 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$78.06M | -$69.39M | DEF 14A filed 2026-04-24 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| 2025-09-30 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$71.28M | -$65.02M | 10-Q filed 2025-11-10 |
| 2025-06-30 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$73.17M | -$66.10M | 10-Q filed 2026-08-10 |
| 2025-03-31 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$63.10M | -$55.34M | 10-Q filed 2026-08-10 Assembled from more than one filing; the filing above is only the newest of them. |
| 2024-12-31 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$75.88M | -$67.22M | DEF 14A filed 2026-04-24 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| 2024-09-30 | —Revenue: unreported by this company. | —Gross profit: unreported by this company. | -$58.69M | -$49.02M | 10-Q filed 2025-11-10 |
- Assets
- $1.34B
- Equity (not reported by this company)
- —Equity: unreported by this company.
Balance as of 2026-06-30.
Ten years
| Fiscal year end | Revenue | Operating income | Net income | Free cash flow |
|---|---|---|---|---|
| 2025-12-31 | — | -$285.60M | -$255.84M | -$232.60M |
| 2024-12-31 | — | -$216.87M | -$182.15M | -$172.33M |
| 2023-12-31 | — | -$93.00M | -$83.98M | -$74.93M |
Company filings
4 offering filings in 12 months
events
Agreement ended, Acquisition or sale completed, Listing standard notice, Shareholder rights changed, Change in control, Executive or director change, Bylaws or fiscal year change
Agreement endedAcquisition or sale completedListing standard noticeShareholder rights changedChange in controlExecutive or director changeBylaws or fiscal year changeSep 38-KExecutive or director change, Shareholder vote results
Executive or director changeShareholder vote resultsAug 118-KResults
ResultsAug 108-KMaterial agreement, Shareholder vote results, Regulation FD disclosure, Other event
Material agreementShareholder vote resultsRegulation FD disclosureOther eventJun 228-KMaterial agreement
Material agreementJun 228-KShareholder vote results
Shareholder vote resultsJun 128-K
5% owners ()
Venrock Healthcare Capital Partners III, L.P.
Stake update
Fairmount Funds Management LLC
Stake update
Wellington Management Group LLP
Stake update
T. Rowe Price Investment Management, Inc.
Stake update
FMR LLC
Stake update
Insiders, politicians and funds
Insider trades, last 90 days
Dambkowski Carl
Chief Medical Officer
Sale$737,935Aug 7, 8:00 PM ET
HENDERSON MICHAEL THOMAS
Chief Executive Officer, Director
Sale$2,672,600Jul 10, 8:00 PM ET
Politician trades, last 90 days
No politician trades filed in the last 90 days.
Funds
None of the tracked funds held this at their last 13F.
News
Stories that named APGE, and the market events around them.
Sign in to see thisBoard
Recent signals
Signals open up here once a member has posted about APGE.
Signals are informational.
Posts · 0
No posts yet.
nakagai
Signals on APGE come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Members post on the APGE board